


GENETIC DIAGNOSIS OF ENDOCRINE DISORDERS

SECOND EDITION



EDITED BY
ROY E. WEISS
SAMUEL REFETTOFF



GENETIC DIAGNOSIS OF ENDOCRINE DISORDERS

SECOND EDITION


Edited by

ROY E. WEISS

Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA


SAMUEL REFETOFF

*Departments of Medicine, Pediatrics and Committee on Genetics,
University of Chicago, Chicago, IL, USA*



AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an Imprint of Elsevier



Academic Press is an imprint of Elsevier
125, London Wall, EC2Y 5AS, UK
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA
225 Wyman Street, Waltham, MA 02451, USA
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK

Copyright © 2016 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Medical Disclaimer

Medicine is an ever-changing field. Standard safety precautions must be followed, but as new research and clinical experience broaden our knowledge, changes in treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current product information provided by the manufacturer of each drug to be administered to verify the recommended dose, the method and duration of administrations, and contraindications. It is the responsibility of the treating physician, relying on experience and knowledge of the patient, to determine dosages and the best treatment for each individual patient. Neither the publisher nor the authors assume any liability for any injury and/or damage to persons or property arising from this publication.

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-12-800892-8

For information on all Academic Press publications
visit our website at <http://store.elsevier.com/>

Typeset by Thomson Digital

Printed and bound in the United States of America



List of Contributors

- Milad Abusag** University of Pittsburgh Medical Center – Horizon (UPMC-Horizon), Pittsburgh, PA, USA
- Valerie Arboleda** Department of Pathology and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- Andrew Arnold** Center for Molecular Medicine and Division of Endocrinology and Metabolism, University of Connecticut School of Medicine, Farmington, CT, USA
- Guillaume Assié** Département Hospitalo-Universitaire, Faculté de Médecine Paris Descartes, Université Paris, Paris, France; Service des Maladies Endocriniennes et Métaboliques, Centre de Recherche des Maladies Rares de la Surrénale, Hôpital Cochin, India
- Albert Beckers** Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège, Belgium
- Graeme I. Bell** Section of Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, IL, USA
- Xavier Bertagna** Département Hospitalo-Universitaire, Faculté de Médecine Paris Descartes, Université Paris, Paris, France; Service des Maladies Endocriniennes et Métaboliques, Centre de Recherche des Maladies Rares de la Surrénale, Hôpital Cochin, India
- Jérôme Bertherat** Département Hospitalo-Universitaire, Faculté de Médecine Paris Descartes, Université Paris, Paris, France; Service des Maladies Endocriniennes et Métaboliques, Centre de Recherche des Maladies Rares de la Surrénale, Hôpital Cochin, India
- Gemma V. Brierley** Metabolic Research Laboratories, University of Cambridge Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
- Silvia Cantara** Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
- David Carmody** Section of Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, IL, USA
- Jane Hvarregaard Christensen** Department of Biomedicine, Aarhus University, Aarhus, Denmark
- Karine Clément** Institute of Cardiometabolism and Nutrition (ICAN), Nutriomique, University Pierre et Marie Curie-Paris, Pitie-Salpêtrière Hospital, Paris; Nutrition Department, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
- Shelly Cummings** Myriad Genetic Laboratories, Inc., Salt Lake City, UT, USA
- Adrian F. Daly** Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège, Belgium
- Johnny Deladoëy** Endocrinology Service and Research Center, Sainte-Justine Hospital and Department of Pediatrics, Université de Montréal; Department of Biochemistry, Université de Montréal, Montréal, Québec, Canada
- Koen M. Dreijerink** Department of Clinical Endocrinology, University Medical Center, Utrecht, the Netherlands
- Béatrice Dubern** Institute of Cardiometabolism and Nutrition (ICAN), Nutriomique, University Pierre et Marie Curie-Paris, Pitie-Salpêtrière Hospital, Paris; Nutrition and Gastroenterology Department, Armand-Trousseau Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
- Alexandra M. Dumitrescu** Department of Medicine, The University of Chicago, Chicago, IL, USA
- David A. Ehrmann** Section of Endocrinology, Diabetes, and Metabolism, The University of Chicago, Maryland, Chicago, IL, USA
- Douglas B. Evans** Medical College of Wisconsin, Milwaukee, WI, USA
- Murray J. Favus** Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago, Chicago, IL, USA
- Abhimanyu Garg** Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, Distinguished Chair in Human Nutrition Research, Center for Human Nutrition, UT Southwestern Medical Center, Dallas, TX, USA
- Jennifer L. Geurts** Medical College of Wisconsin, Milwaukee, WI, USA
- Helmut Grasberger** Department of Medicine, University of Michigan, Ann Arbor, MI, USA
- Siri Atma W. Greeley** Section of Endocrinology, Diabetes and Metabolism, The University of Chicago; Departments of Pediatrics and Medicine, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, IL, USA
- Lionel Groussin** Département Hospitalo-Universitaire, Faculté de Médecine Paris Descartes, Université Paris, Paris, France; Service des Maladies Endocriniennes et Métaboliques, Centre de Recherche des Maladies Rares de la Surrénale, Hôpital Cochin, India
- Jo W. Höppener** Department of Molecular Cancer Research, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands

- Leslie Hoffman** Columbus Endocrinology, Columbus, OH, USA
- Michael F. Holick** Department of Medicine, Section of Endocrinology, Nutrition, and Diabetes, Vitamin D, Skin and Bone Research Laboratory, Boston University Medical Center, Boston, MA, USA
- Elbert S. Huang** Department of Medicine, Section of General Internal Medicine, The University of Chicago, Chicago, IL, USA
- Hélène Huvenne** Department of Pediatrics, Saint-Vincent de Paul Hospital, GHICL, Lille; Institute of Cardiometabolism and Nutrition (ICAN), Nutriomique, University Pierre et Marie Curie-Paris, Pitié-Salpêtrière Hospital, Paris, France
- Vivian Hwa** Cincinnati Children's Hospital, Cincinnati, OH, USA
- Andrea L. Jones** Division of Pediatric Endocrinology, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Loren J. Joseph** Molecular Diagnostics Laboratory, The University of Chicago Medical Center, The University of Chicago, Chicago, IL, USA
- George J. Kahaly** Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany
- Dorit Koren** Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, University of Chicago, Chicago, IL, USA
- Kelly Lauter** Department of Medicine, Endocrine Division, Massachusetts General Hospital, Boston, MA, USA
- Rossella Libé** Département Hospitalo-Universitaire, Faculté de Médecine Paris Descartes, Université Paris, Paris, France; Service des Maladies Endocriniennes et Métaboliques, Centre de Recherche des Maladies Rares de la Surrénale, Hôpital Cochin, India
- Thera P. Links** Department of Clinical Endocrinology, University Medical Center, Groningen, Groningen, the Netherlands
- Cornelis J. Lips** Department of Clinical Endocrinology, University Medical Center, Utrecht, the Netherlands
- Michael J. McPhaul** Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX
- Rochelle N. Naylor** Departments of Pediatrics and Medicine, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, IL, USA
- Maria I. New** Mount Sinai School of Medicine, Department of Pediatrics, New York, NY, USA
- Sarah M. Nielsen** Center for Clinical Cancer Genetics and Global Health, Department of Medicine, University of Chicago, Chicago, IL, USA
- Saraj Nimkarn** Bumrungrad International Hospital, Department of Pediatrics, Bangkok, Thailand
- Stephen O'Rahilly** Metabolic Research Laboratories, University of Cambridge Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
- Furio Pacini** Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
- Andrew Palladino** Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Louis H. Philipson** Section of Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, IL, USA
- Joachim Pohlenz** Pediatric Endocrinology, Department of Pediatrics, Johannes Gutenberg University, Mainz, Germany
- Sally Radovick** Division of Pediatric Endocrinology, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Margarita Raygada** Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, (PDEGEN), Eunice Kenney Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA
- Samuel Refetoff** Departments of Medicine, Pediatrics and Committee on Genetics, University of Chicago; Department of Medicine, The University of Chicago, Chicago, IL, USA
- Thereasa A. Rich** Myriad Genetic Laboratories, Denver, Co, USA
- Inne Borel Rinkes** Department of Surgery, University Medical Center, Utrecht, the Netherlands
- Søren Rittig** Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
- Christopher J. Romero** Division of Pediatric Endocrinology, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Ron G. Rosenfeld** Oregon Health & Science University, Portland, OR, USA
- Liliya Rostomyan** Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège, Belgium
- David B. Savage** Metabolic Research Laboratories, University of Cambridge Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
- Robert K. Semple** Metabolic Research Laboratories, University of Cambridge Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
- Julie Støtj** Department of Clinical Medicine – Medical Research Laboratory, Aarhus University, Aarhus, Denmark

- Constantine A. Stratakis** Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, (PDEGEN), Eunice Kenney Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA
- Bernard S. Strauss** Department of Molecular Genetics and Cell Biology, The University of Chicago, Chicago, IL, USA
- Marc Timmers** Department of Molecular Cancer Research, University Medical Center, Utrecht, the Netherlands
- Patrick Tounian** Institute of Cardiometabolism and Nutrition (ICAN), Nutriomique, University Pierre et Marie Curie-Paris, Pitie-Salpêtrière Hospital, Paris; Nutrition and Gastroenterology Department, Armand-Trousseau Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
- Gerlof D. Valk** Department of Clinical Endocrinology, University Medical Center, Utrecht, the Netherlands
- Anouk N.A. van der Horst-Schrivers** Department of Clinical Endocrinology, University Medical Center, Groningen, the Netherlands
- Rob B. van der Luijt** Department of Medical Genetics, University Medical Center, Utrecht, the Netherlands
- Bernadette P.M. van Nesselrooij** Department of Medical Genetics, University Medical Center, Utrecht, the Netherlands
- Guy Van Vliet** Endocrinology Service and Research Center, Sainte-Justine Hospital and Department of Pediatrics, Université de Montreal, Montreal, Quebec, Canada
- Eric Vilain** Department of Human Genetics, Pediatrics, and Medical Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- Menno Vriens** Department of Surgery, University Medical Center, Utrecht, the Netherlands
- Tracy S. Wang** Medical College of Wisconsin, Milwaukee, WI, USA
- Roy E. Weiss** Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
- Mabel Yau** Mount Sinai School of Medicine, Department of Pediatrics, New York, NY, USA
- Stephan Zuchner** Department of Human Genetics and Neurology, Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA

Preface to the First Edition

Imagine the skepticism of a physician of the 1950s or 1960s if told that genetic testing would be used to diagnose specific complex endocrine disorders. Until relatively recently major abnormalities of the endocrine system were diagnosed, treated, and monitored with clinical assessment only. It was the clinical acumen of the astute physician that enabled correct diagnosis and determined which gland was responsible for producing too much or too little of a given hormone. The clinically pertinent markers of endocrine diseases were physiological measurements of basal metabolic rates, body weight, and urine output, which we now term the “physiologic” era of endocrinology.

Despite the discovery of insulin by Banting, Best, Macleod, and Collip in 1921 and its use for humans in 1923, it was only with Rosalyn Yalow and Salomon Berson’s seminal report on the immunoassay of endogenous plasma insulin in 1960 that the “assay” period of endocrinology was introduced. This momentous methodological breakthrough enabled the endocrinologist to assay hormones previously impossible to measure at physiologically or pathologically relevant levels. The competitive protein-binding assay facilitated measurement of nanomolar or picomolar concentrations of hormones in plasma and tissues. Adaptation for other compounds further extended the field until 20 years ago, when “molecular” or “genetic” endocrinology evolved with the discovery of genes for insulin and growth hormone. Despite Paul Wermer’s 1954 publication of the first clearly inherited endocrine disease “familial adenomatosis” (*American Journal of Medicine*, 1954, pp. 363–371), it is only with access to the genetic tools of the new millennium that the clinician can now precisely identify the genetic defects causing a disease and apply rational therapy. In *Genetic Diagnosis of Endocrine Disorders* we present to the clinician a straightforward, clinically relevant review of important genetic tests currently in use for the diagnosis of endocrine disorders, and practical information as to where these tests are performed.

Some endocrine disorders follow familial patterns of inheritance, while others may represent sporadic mutations. In both cases, identification of the mutation associated with the particular disease ideally allows the physician to test other family members, who may be asymptomatic. For example, in the case of a mutation with potential for adverse outcome such as medullary thyroid cancer. Physician and patient can now con-

sider prophylactic thyroidectomy, for harboring such a gene prior to actual presentation of clinical disease; an approach possible only with the endocrine “genetic” revolution. Correlation of phenotype and genotype is frequently concordant, though in some instances the same genotype may cause different subtle or obvious phenotypes. An example would be patients with resistance to thyroid hormone who, despite identical mutations in the thyroid hormone receptor gene, may present with different phenotypes. The contrary example would be where the same phenotype may be due to different genotypes, as is occasionally the case in adrenal hyperplasias. Even in “truly” monogenic diseases, the genetic background of affected individuals may substantially modulate the phenotype. Thus, while genetic diagnosis is a critical part of the armamentarium of the modern-day Banting and Best, correlation of the genetic abnormality with its physiological manifestations remains crucial. Knowledge of which genetic tests to order must be supported by a full understanding of the genetic information they provide. The health care team responsible for diagnosis and follow-up, should ensure inclusion of the patient’s family/primary care physician and a genetic counselor.

Genetic Diagnosis of Endocrine Disorders was initially conceived for purely selfish reasons. For our own use we needed a comprehensive clinical practice handbook for the genetic diagnoses of endocrine diseases. We therefore invited world experts to summarize the full range of currently available genetic endocrine diagnoses for our text. Initially we had to justify to ourselves taking time from our research to edit yet another endocrine book. However, the real advantage of editing this compilation of excellent reviews by renowned experts is the knowledge we have acquired in doing so. We hope that the reader will as well.

Our many thanks to those who have so graciously contributed to *Genetic Diagnosis of Endocrine Disorders* as well as to Fay, Heather, and our children who have been unswerving in their support of our careers. We would also like to acknowledge the support of the National Institute of Health (grants DK15070, DK07011, DK20595, and RRO4999), the Abrams and Esformes Endowments, and the Sherman family.

Roy E. Weiss, MD, PhD, FACP, FACE
Samuel Refetoff, MD, PhD

Preface to the Second Edition

The first edition of Genetic Diagnosis of Endocrine Disorders was published five years ago. Since then, the revolution of Precision Medicine has taken center stage in medical diagnosis, and those treating endocrine diseases need the appropriate ammunition to approach their patient's problems. There is rarely an article in the medical literature involving endocrine diseases, which does not mention a new gene or mutation. An encyclopedic compilation of the totality of genes involved in endocrine diagnosis does not lend itself to a printed text, which by nature is static. Therefore, the purpose of this book is to present emerging concepts to practicing pediatric and adult endocrinologists, students in the field, and genetic counselors, and review the most common genetic causes for endocrine disorders. Given the increasing affordability and availability of whole exome sequencing, the genetic cause of many more diseases will be identified, and there will be additional

genes to know. New genetic conditions will emerge. In addition the role of epigenetics miRNAs, and enhancers in the cause of genetic endocrine disorders is quickly being recognized.

The purpose of having a genetic diagnosis should enable the patient and physician to understand the basis for the disease and thereby apply rationale and targeted therapy. In addition, based on the genetic information, decisions can be made regarding risks in asymptomatic relatives, allowing for preemptive.

Another reason for the second edition was based on the favorable reviews of the first edition and being urged by those reviewers to write a new edition.

We thank our returning and new authors for their outstanding contributions to this second edition.

*Roy E. Weiss, Miami
Samuel Refetoff, Chicago*

Contents

List of Contributors	ix
Preface to the First Edition	xiii
Preface to the Second Edition	xv

I

INTRODUCTION

1. Mechanisms of Mutation

BERNARD S. STRAUSS

Introduction	3
The Types of Mutation	3
The Mechanisms of Mutation	7
The Role of Technology	11
Double-Strand Break Repair-Related Mechanisms	12
Mobile Insertion Elements	13
The Human Mutation Rate	15
The Phenotypic Effect of Mutations	16
Conclusion and Summary	16
References	17

II

PANCREAS

2. A Clinical Guide to Monogenic Diabetes

DAVID CARMODY, JULIE STØY, SIRI ATMA W. GREELEY,
GRAEME I. BELL, LOUIS H. PHILIPSON

Introduction	21
Clinical Presentation	21
Genetic Testing	26
Conclusions	28
References	28

3. Hypoglycemia

DORIT KOREN, ANDREW PALLADINO

Introduction	31
Genetic Pathophysiology	33
Summary	70
References	71

III

PITUITARY

4. Functioning Pituitary Adenomas

ALBERT BECKERS, LILIYA ROSTOMYAN, ADRIAN E. DALY

Introduction	79
--------------	----

Genetic Pathophysiology of Pituitary Adenomas	80
Genetic Screening in Functioning Pituitary Adenomas	81
MEN1	81
MEN1-Related Pituitary Tumors	82
Carney Complex (CNC)	83
Multiple Endocrine Neoplasia 4 (MEN4)	84
Familial Isolated Pituitary Adenomas (FIPA)	84
References	88

5. Diabetes Insipidus

JANE HVARREGAARD CHRISTENSEN, SØREN RITTIG

Introduction	93
Types of Diabetes Insipidus	93
Familial Types of Diabetes Insipidus	94
Clinical Diagnosis	98
Genetic Testing	98
References	100

6. States of Pituitary Hypofunction

CHRISTOPHER J. ROMERO, ANDREA L. JONES, SALLY RADOVICK

Introduction	103
Genetic Pathophysiology	103
Diagnosis, Genetic Testing, and Interpretation	108
Treatment	108
References	110

IV

THYROID

7. Congenital Defects of Thyroid Hormone Synthesis

HELMUT GRASBERGER, SAMUEL REFETTOFF

Introduction	117
Pathophysiology and Genetics of Specific Dyshormonogenesis Defects	117
Availability of Genetic Testing	122
Conclusions	123
References	123

8. Developmental Abnormalities of the Thyroid

JOACHIM POHLENZ, GUY VAN VLIET, JOHNNY DELADOËY

Introduction	127
TSH Receptor Gene Mutations (Loss of Function)	128
PAX8 Gene Mutations	129
TTF1/NKX2-1 Gene Mutations	130
TTF2 (FOXE 1 or FKHL15) Gene Mutations	130
GLIS3 Gene Mutations	131
NKX2-5 Gene Mutations	132

Syndromes Associated with CH from Thyroid Dysgenesis	132
TSHR Gene Mutations (Gain of Function)	132
Treatment	133
Conclusions	133
References	133

9. Syndromes of Impaired Sensitivity to Thyroid Hormone

ROY E. WEISS, ALEXANDRA M. DUMITRESCU, SAMUEL REFETOFF

Introduction	137
Overview of Described and Putative Defects in Syndromes of Impaired Sensitivity to Thyroid Hormone	138
Resistance to Thyroid Hormone (RTH)	139
Thyroid Hormone Cell Transporter Defect	144
Thyroid Hormone Metabolism Defect	147
References	148

10. Molecular Diagnosis of Thyroid Cancer

FURIO PACINI, SILVIA CANTARA

Introduction	153
Oncogene Rearrangements	153
Gene Mutations	154
Other Genetic Alterations	155
Application of Molecular Findings to the Clinical Diagnosis of Thyroid Cancer	156
miRNAs in Thyroid Lesions	158
Microarray	158
mRNA Expression	158
Conclusion	159
References	159

V

PARATHYROID/BONE

11. Genetics of Hyperparathyroidism Including Parathyroid Cancer

ANDREW ARNOLD, KELLY LAUTER

Introduction	165
Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT), HRPT2, and Parathyroid Carcinoma	166
Familial Hypocalciuric Hypercalcemia (FHH) and Neonatal Severe Hyperparathyroidism (NSHPT)	168
Autosomal Dominant Hypoparathyroidism	170
Familial Isolated Hyperparathyroidism	171
Summary	171
References	172

12. Genetic Diagnosis of Skeletal Dysplasias

MURRAY J. FAVUS

Introduction	173
Sclerosing Bone Disorders	173
Disorders of Defective Mineralization	181

Dysplasias of Bone and Cartilage with Normal or Low Bone Mass	183
References	186

13. Vitamin D Disorders

MICHAEL E. HOLICK

Introduction	191
Calcium, Phosphorus, and Vitamin D Metabolism	191
Vitamin D Deficiency and Rickets	193
Genetic Causes of Rickets – Osteomalacia: Disorders in Vitamin D Metabolism and Recognition	193
Genetic Causes of Rickets: Hypophosphatemic Disorders	195
Genetic Causes of Hypercalcemia Associated with Alterations in Vitamin D Metabolism	197
References	198

VI

ADRENAL

14. Congenital Adrenal Hyperplasia

MABEL YAU, SAROJ NIMKARN, MARIA I. NEW

Introduction	203
Genetic Pathophysiology	204
Diagnosis: Genetic Testing and Interpretation	205
Treatment	207
References	209

15. Genetics of Adrenocortical Tumors (ACT) and Hypersecretory Syndromes

ROSSELLA LIBÉ, GUILLAUME ASSIÉ, LIONEL GROUSSIN,
JÉRÔME BERTHERAT, XAVIER BERTAGNA

Introduction	211
Conclusions	216
References	217

16. Hereditary Syndromes Involving Pheochromocytoma and Paraganglioma

JENNIFER L. GEURTS, THEREASA A. RICH, DOUGLAS B. EVANS,
TRACY S. WANG

Multiple Endocrine Neoplasia Type 2	222
Von Hippel–Lindau Syndrome (VHL)	224
Neurofibromatosis Type 1	225
Hereditary Paraganglioma/Pheochromocytoma Syndromes	226
Genetic Risk Assessment in Patients with Apparently Sporadic Pheochromocytoma	229
Summary	231
References	232

17. Genetic Conditions Associated with Congenital Adrenocortical Insufficiency or Glucocorticoid and/or Mineralocorticoid Resistance

MARGARITA RAYGADA, CONSTANTINE A. STRATAKIS

Introduction	235
--------------	-----

Genetics of Embryology and Function of the Adrenal Glands	235
Genetic Defects Causing CAI: An Overview and a Comment on Treatment	236
Specific Genetic Conditions Associated with CAI	238
Genetic Conditions Associated with Resistance to Glucocorticoids or Mineralocorticoids	242
References	244

VII

REPRODUCTIVE

18. Genetic Considerations in the Evaluation of Menstrual Cycle Irregularities

MILAD ABUSAG, DAVID A. EHRMANN, LESLIE HOFFMAN

Introduction	249
Ovarian Disorders	249
Adrenal Disorders	254
Clinical and Laboratory Evaluation	256
Conclusions	256
References	256

19. Disorders of Sex Development

VALERIE ARBOLEDA, ERIC VILAIN

Disorders of Sex Development	259
Disorders of Sex Determination	259
Disorders of Sex Differentiation	268
High-Throughput Sequencing in the Diagnosis of Disorders of Sex Determination	273
Conclusions	274
References	274

20. Androgen Insensitivity Due to Mutations of the Androgen Receptor

MICHAEL J. MCPHAUL

Male Phenotypic Development is Controlled by Androgens	279
The Androgen Receptor	279
Measurements of AR and its Function	281
The Modulation of Gene Expression by the AR	282
Androgen Insensitivity: A Spectrum of Abnormalities Caused by Defects of the AR	282
The Genetic Basis of Androgen Insensitivity	283
Disruption of the Primary Amino Acid Sequence	283
Alterations of the DBD	283
Alterations of LBD Structure	283
Mutations within the Amino Terminus	284
Mutations that Cause Decreased Levels of Ligand Binding	284
Phenotype and Genotype in Patients with Various Forms of Androgen Insensitivity	285
Spinal and Bulbar Muscular Atrophy and Prostate Cancer	285
Diagnostic Resources	285
References	286

VIII

ADIPOCYTE

21. Obesity

HÉLÈNE HUVENTE, PATRICK TOUNIAN, KARINE CLÉMENT, BÉATRICE DUBERN

Introduction	291
Genetic Pathophysiology	292
Diagnosis Genetic Testing and Interpretation	299
Treatment	300
References	302

22. Syndromes of Severe Insulin Resistance and/or Lipodystrophy

ROBERT K. SEMPLE, DAVID B. SAVAGE, GEMMA V. BRIERLEY, STEPHEN O'RAHILLY

Introduction	307
Genetic Pathophysiology	311
Diagnosis, Genetic Testing, and Interpretation	317
Treatment	321
References	322

23. Lipodystrophies

ABHIMANYU GARG

Introduction	325
Autosomal Recessive Lipodystrophies	325
Autosomal Dominant Lipodystrophies	331
References	336

IX

MULTISYSTEM DISORDERS

24. Multiple Endocrine Neoplasia Type 1 (MEN1)

CORNELIS J. LIPS, GERLOF D. VALK, KOEN M. DREIJERINK, MARC TIMMERS, ROB B. VAN DER LUIJT, THERA P. LINKS, BERNADETTE P.M. VAN NESSELROOIJ, MENNO VRIENS, JO W. HÖPPENER, INNE BOREL RINKES, ANOUK N.A. VAN DER HORST-SCHRIJVERS

Introduction	343
Genetic Pathophysiology of MEN1	349
MEN1 Mutation Analysis	352
Treatment	355
Recommendations for the Future	356
Conclusions	356
References	356

25. Genetics of Polyglandular Failure

GEORGE J. KAHALY

Definition, Incidence, Prevalence	361
Clinical Spectrum	361

Genetic Pathophysiology	362
Diagnosis, Genetic Testing, and Interpretation	367
Management	369
References	370

X

GROWTH

26. Genetic Diagnosis of Growth Failure

RON G. ROSENFELD, VIVIAN HWA

Introduction	377
Genetic Pathophysiology	379
Diagnosis: Genetic Testing and Interpretation	383
Treatment	384
References	384

XI

MISCELLANEOUS

27. Cost-Effectiveness of Genetic Testing for Monogenic Diabetes

ROCHELLE N. NAYLOR, SIRI ATMA W. GREELEY,
ELBERT S. HUANG

Cost of Diabetes Care	389
Heterogeneity of Diabetes Mellitus	389
Monogenic Diabetes	389
Precision Medicine in Monogenic Diabetes	389
Considerations in Genetic Testing for Monogenic Diabetes	390
The Role of Cost-Effectiveness Analysis in Healthcare	391
Cost-Effectiveness Analysis of Monogenic Diabetes	392
Future Studies of Cost-Effectiveness Analysis in Monogenic Diabetes	395
Conclusions	395
References	395

28. Genetic Counseling: The Role of Genetic Counselors on Healthcare Providers and Endocrinology Teams

SARAH M. NIELSEN, SHELLY CUMMINGS

Introduction	397
The Genetic Counseling Profession	397

The Role of Genetic Counselors on the Healthcare Provider Team	398
The Genetic Counseling Process	401
The Pedigree: Medicine and Art	403
Pedigree Analysis and Risk Perception	404
Summary	407
References	407

29. Setting Up a Laboratory

LOREN J. JOSEPH

Introduction	409
Regulations for Diagnostic Genetic Laboratories	409
The Preanalytic Phase	412
DNA Preparation	413
Analytic Phase	414
Methods – General PCR	415
Methods – Real-Time and Digital PCR	416
Methods – Microarrays	417
Methods – Methylation Analysis	417
Methods – Sequencing	418
Bioinformatics for NGS	420
Quality Assurance for NGS	421
General Hardware and Software Considerations	421
Postanalytic Phase	423
Summary	424
References	424

30. Introduction to Applications of Genomic Sequencing

STEPHAN ZUCHNER

Overview	427
From Human Genetics to Genomics	427
Excess of Rare Variation in the Human Genome	428
Data Sharing Becomes Essential	429
PNPLA6 Gene Identification – An Example for a Number of Trends in Genomics	430
Conclusions	431
References	432

Index	435
-------	-----

P A R T I

INTRODUCTION

1	<i>Mechanisms of Mutation</i>	3
---	-------------------------------	---

1

Mechanisms of Mutation

Bernard S. Strauss

Department of Molecular Genetics and Cell Biology, The University of Chicago, Chicago, IL, USA

INTRODUCTION

Darwin realized the need for variation to provide a basis for natural selection, but he had no way of understanding the mechanisms by which such variation arose. Vague ideas of the origin of variation in the late nineteenth century gave way to the term mutation, coined by deVries to describe the discontinuous variation associated with Mendelian traits.¹ Genes were first recognized and defined by mutations with an extreme phenotype (see Table 1.1). Further progress led to conceptualizing the gene as a more complex structure with multiple “sites” for mutation available within the same gene. The nature of such sites was not clear, nor was the relationship between the physiological effects of gene mutations and the structural change involved. A typical pre-Watson-Crick examination question, “what is a gene?” could be answered in terms of function, of mutation, or of recombination and the question for geneticists was the relationship between these definitions.

Modern understanding of the mechanism of mutation is based on the Watson-Crick DNA structure. Recognizing the importance of nucleotide sequence followed by the deciphering of the genetic code led to a change from a biological and formalistic or mathematical view of mutation to a more biochemical approach. This chapter presents the problem of mutation as mainly one of biochemistry.

The immediate response of investigators to the Watson-Crick structure was to focus attention on the base changes that resulted in mutation and on the chemical changes that might alter base pairing.² The specificity of particular mutagenic agents was initially ascribed to chemical changes in either the incoming or template nucleotide, resulting in altered pairing properties, mainly involving hydrogen bonding. Benzer and Freese³ and Brenner et al.⁴ defined mutation in terms of substitutions, additions, and deletions of nucleotides. DNA in eukaryotes is organized into discrete chromosomes.

Changes in the structure (rearrangements and translocations) and numerical distribution of these chromosomes that leave a viable organism are also mutation, but it is only recently, with the availability of extensive DNA sequence information, that these changes can even be partially accounted for biochemically.

Advances in our understanding of the complex biochemistry of DNA replication and its interaction with the various DNA repair and recombination pathways has led to a more mechanistic approach to understanding mutation (Fig. 1.1). The discovery in the late 1990s of a series of DNA polymerases with altered fidelity and ability to replicate past damaged sites in DNA⁵ advanced a view of mutation as an event involving both initial changes in the DNA and the interaction of these changes with the protein complement of the cell. Most recently, the advent of rapid and relatively inexpensive DNA sequencing technology has permitted a direct measurement of normal human mutation rates and the recognition that *de novo* mutation plays a role in human disease. The identification of thousands of mutational changes in individual tumors, only a small minority of which are involved as “drivers” in the etiology of the tumors, has permitted recognition of a set of mutational “signatures” that implicate particular repair processes in the generation of the mutations. The observation of numerous closely linked mutations in tumor cells suggests the operation of unique mutagenic mechanisms whose operation in normal cells remains an open question.

THE TYPES OF MUTATION

Mutations are defined in this chapter as changes in the parental sequence of the DNA (Table 1.1). This definition is not without problems, since it is sometimes difficult to distinguish such changes from the normal process of recombination. Mutations include single

TABLE 1.1 Special Abbreviations and Definitions

Term/Abbreviations	Definition
Abasic (apurinic/apyrimidinic) site	Site in DNA missing a base attached to the 1'-position of the sugar
APOBEC/AID	Apolipoprotein B mRNA editing enzyme (APOBEC) and activation-induced deaminase (AID). A family of cytidine deaminases
Aneuploidy	Eucaryotic cells with the normal diploid ($2n$) number of chromosomes are "euploid." "Haploid" cells are n . "Polyploid" cells are $3n$, $4n$, etc. "Aneuploid" cells are $2n \pm$ a number other than n
Base excision repair (BER)	A repair mechanism in which single nucleotide bases are removed and replaced by a patch of one or, at most, a few nucleotides
Chromothripsis	Multiple localized chromosome rearrangements occurring in a single event and in one or a few chromosomes
Copy number variation (CNV)	Altered number of copies of a gene or extended DNA sequence present in the genome
Double-strand break repair (DSBR)	Joining together of two DNA fragments to make a single molecule
Epigenetic	Heritable changes in gene expression that cannot be tied to DNA sequence variation and involving the active perpetuation of local chromatin states
Fidelity	A measure of the relative ability of DNA polymerases to insert the "correct" complementary base
Frameshift mutation	The insertion or deletion of a number of nucleotides not divisible by 3, properly speaking in a coding region of a gene. Largely replaced by the term "indel."
Genome	(1) The complete set of genetic material present in an organism. (2) The complete sequence of the DNA in an organism
Genotype	The genetic constitution of an organism
Holliday junction	A mobile junction formed in recombination between four strands of DNA. It is "resolved" by specific enzymes to regenerate two double-stranded molecules
Homologous recombination (HR)	A DSBR process involving the use of an allelic DNA sequence as a source of information
Indel	Insertion or deletion of a small number of nucleotides in the DNA structure
Insertional mutagenesis	Mutation by insertion of one or more nucleotides. Often used to denote inactivation of the genes by insertion of large transposable elements
Inversion	A rearrangement of the chromosome so that the order of the nucleotide pairs is reversed: if the normal order is ABCDEF, the order AEDCBF would constitute an inversion
Kataegis	Multiple, localized mutations, mostly C→T
L1 element	A common retrotransposon found in the human genome
Microhomology-mediated end joining (MMEJ)	An end joining DSBR mechanism utilizing the homology of a relatively few bases to orient the broken strands
Mismatch repair (MMR)	An excision repair process mainly devoted to correcting errors in replication
Missense mutation	A change in a gene, which results in a change in the meaning of a codon, e.g., the change from GAA (glutamic acid) to GUA (valine)
Mobile element insertion (MEI)	See transposon below. Mutational event in which a mobile element is inserted at a new position in the genome
Mutator	A mutation, often of a repair gene, that has the effect of increasing the spontaneous mutation rate
Nucleotide excision repair (NER)	The paradigm of an excision repair pathway. NER recognizes a wide range of damage and proceeds by cutting out and replacing an extensive series of nucleotides
Nonallelic homologous recombination (NAHR)	HR in which the complement is a homologous sequence other than the normal allele and which can lead to chromosome aberrations
Nonsense mutation	A mutation that results in one of the termination codons UAA, UAG, or UGA
Phenotype	The observable traits of an organism
Point mutation	A mutation involving one or a few nucleotides as distinguished from insertions, deletions, and duplications involving hundreds, thousands, or more nucleotides

TABLE 1.1 Special Abbreviations and Definitions (*cont.*)

Term/Abbreviations	Definition
Proofreading	In DNA synthesis, the process where an exonuclease checks a newly-inserted nucleotide for goodness of fit. Sometimes referred to as editing
Pseudogene	A copy of a gene made inactive by the accumulation of mutations and often devoid of introns
Retrotransposon	A transposable element that can shift its position in DNA via an RNA intermediate
Reactive oxygen species (ROS)	Chemically reactive radicals containing oxygen formed in metabolism and produced in clusters by ionizing radiation
Somatic hypermutation (SHM)	Process producing multiple mutations in mature B cells, mostly but not exclusively in the immunoglobulin gene during antibody maturation
Single nucleotide variation (SNV)	A point mutation involving a single nucleotide pair
<i>Syn/anti</i> base configuration	In the <i>anti</i> configuration, the bulky part of the base of a nucleoside or nucleotide rotates away from the sugar. In the <i>syn</i> configuration the bulky part rotates over the sugar
Synonymous/silent mutation	A nucleotide change that does not change the meaning of a codon, e.g., the change from GGU (glycine) to GGA (glycine). Not all synonymous mutations are silent, that is, without phenotypic effect
Translocation	Attachment of a segment of one chromosome to a different (nonhomologous) chromosome
Transposition	The movement of a transposable element from one position in the genome to another
Transition	The mutational change from a purine to another purine or a pyrimidine to another pyrimidine. G \leftrightarrow A and C \leftrightarrow T are the possible transitions
Transposon, mobile element (ME)	A DNA sequence able to move from one position to another within the genome. Movements are generally rare and are catalyzed by special enzymes coded for by the transposon
Transversion	The mutational change from a purine to a pyrimidine or a pyrimidine to a purine. A \leftrightarrow T, G \leftrightarrow C, C \leftrightarrow A are possible transversions
Translesion synthesis (TLS)	Synthesis of DNA by specialized polymerases utilizing a damaged template
Transcription coupled nucleotide excision repair (TC-NER)	Specialized NER mechanism targeted to genes in the process of transcription
Ubiquitin	A conserved small (76 amino acids in humans) protein, which when covalently added to proteins in single or multiple copies serves as a signal for processes such as degradation and/or changes in conformation

nucleotide variation (SNV), insertion or deletion of small numbers of nucleotides (indels, frameshifts), rearrangements of the DNA sequence, change in the number of copies of larger stretches of DNA (copy number variation, CNV), and changes in the structure (inversions and translocations) or number of chromosomes (aneuploidy). The insertion or movement of transposable elements may affect phenotype and be obviously mutagenic. Nucleotide changes may occur outside the exome, the protein coding region of the genome, and these may or may not have an observable effect on phenotype. This view of mutation as a sequence change anywhere in the genome⁶ is a product of the sequencing revolution, since the recognition of mutation in the pre-sequencing era required some observable change in the phenotype. The definition of mutation as any change in DNA sequence results in classifying sequence changes

that have no obvious phenotypic effect as mutations. There are about 20,000–25,000 human genes, and the exome comprises somewhere about 2% of the total number of nucleotides.⁷ Much of the remainder of the DNA is transcribed into RNA,⁸ and some of this plays an important regulatory role in gene function, but as yet there is no automatic way to predict whether or what a change in DNA sequence will mean for physiology.

The possible single base changes were first cataloged by Ernst Freese and Seymour Benzer.^{3,9} Freese coined the term “transition” to denote the change from one purine to another, or of one pyrimidine to another. The four possible transitions are cytosine (C) to thymine (T) and its reverse, and adenine (A) to guanine (G) and its reverse. Freese defined “transversions” as changes from a purine to a pyrimidine or the reverse. Change from an A or a G to a C or a T, and the reverse C or T to A or G was defined